CWM
NBIX icon

CIBC World Markets’s Neurocrine Biosciences NBIX Stock Holding History

CIBC World Markets’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$488K Buy
+3,441
New +$499K ﹤0.01% 840
2025
Q2 		$518K Sell
4,120
-487
-11% -$55.8K ﹤0.01% 857
2025
Q1 		$510K Buy
4,607
+38
+0.8% +$4.81K ﹤0.01% 1004
2024
Q4 		$624K Sell
4,569
-1,295
-22% -$160K ﹤0.01% 683
2024
Q3 		$676K Buy
5,864
+498
+9% +$68.3K ﹤0.01% 654
2024
Q2 		$739K Buy
5,366
+1,343
+33% +$184K ﹤0.01% 625
2024
Q1 		$555K Buy
4,023
+1,303
+48% +$178K ﹤0.01% 707
2023
Q4 		$358K Buy
+2,720
New +$313K ﹤0.01% 687
2022
Q1 		– Sell
-50,000
Closed -$4.26M – 647
2021
Q4 		$4.26M Buy
+50,000
New +$4.6M 0.02% 286
2021
Q2 		– Sell
-10,087
Closed -$981K – 831
2021
Q1 		$981K Buy
+10,087
New +$1.06M 0.01% 617
2020
Q1 		– Sell
-109,300
Closed -$11.7M – 678
2019
Q4 		$11.7M Buy
+109,300
New +$11.4M 0.08% 236

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CIBC World Markets's NBIX Position: Q4 2025 in Review

CIBC World Markets opened a new position in Neurocrine Biosciences (NBIX) in Q4 2025: 3,441 shares worth $488K. The stake represents ﹤0.01% of the portfolio and ranks #840 among its holdings. This is a return to the name: CIBC World Markets previously reported a position in NBIX as recently as Q2 2025.

CIBC World Markets first reported a position in NBIX in Q4 2019 and has held it in 11 quarters since. The position peaked at $11.7M in Q4 2019. 730 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • CIBC World Markets held 3,441 shares of Neurocrine Biosciences worth $488K as of Q4 2025.
  • Neurocrine Biosciences was a new CIBC World Markets position in Q4 2025.
  • Neurocrine Biosciences made up ﹤0.01% of CIBC World Markets's portfolio in Q4 2025, its #840 holding.
  • CIBC World Markets first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 11 quarters since.
  • CIBC World Markets's Neurocrine Biosciences position peaked at $11.7M in Q4 2019.
  • 730 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on CIBC World Markets's 13F filing for Q4 2025, filed 12 Feb 2026.